AKT1 and neoplasm: Maertens and colleagues have identified increased activation of the PI3K/AKT/mTOR pathway in BRAF/NF1 double mutants, and a combinatorial MEK marker and mTOR inhibitor treatment has proven effective in many MEK inhibitor-resistant neoplasms [58].